Jody Abrams, MD
Ophthalmology · Sarasota, FLNPI 1942229844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $368,128 of the $474,677 with a category attached, or 77.6%. Amgen accounts for 91.4% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $111,738, more than ten times the $7,137 reported in 2019. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 846 payments — averaging $561.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$434K
- ANI Pharmaceuticals, Inc.$26K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$6K
- AbbVie$2K
- AstraZeneca$2K
- Biohaven Pharmaceuticals, Inc.$649
- plus $4K from 26 others
Across 51 payments — averaging $794.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$28K
- Osmotica Pharmaceutical Corp.$7K
- Amgen$5K
What the payments were for
- Consulting fees$31,9887%
- Speaking & faculty fees$368,12878%
- Travel & lodging$53,04711%
- Food & beverage$21,4025%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 493 | $434,029 |
| ANI Pharmaceuticals, Inc. | 50 | $26,458 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $6,374 |
| AbbVie(2 entities) | 83 | $1,794 |
| AstraZeneca | 42 | $1,538 |
| Biohaven Pharmaceuticals, Inc. | 21 | $649 |
| Bausch & Lomb Americas Inc. | 14 | $511 |
| Sun Pharmaceutical Industries Inc. | 12 | $438 |
| Pfizer | 44 | $405 |
| Biogen | 3 | $332 |
| Argenx US, Inc. | 10 | $243 |
| Teva Pharmaceuticals USA, Inc. | 2 | $240 |
| Regeneron Healthcare Solutions, Inc. | 8 | $196 |
| UCB, Inc. | 6 | $152 |
| Sanofi | 2 | $138 |
| Genentech USA, Inc. | 5 | $134 |
| Merz Pharmaceuticals, LLC | 5 | $133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $131 |
| Alcon | 2 | $120 |
| Novartis | 6 | $115 |
| Mallinckrodt Hospital Products Inc. | 1 | $98 |
| Shire North American Group Inc | 1 | $92 |
| Harrow Eye, LLC | 4 | $69 |
| Tarsus Pharmaceuticals, Inc. | 2 | $57 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $51 |
| Alimera Sciences, Inc. | 2 | $42 |
| Coherus Oncology, Inc. | 1 | $35 |
| Ocular Therapeutix, Inc. | 2 | $35 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Notal Vision, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$417,646
- PURIFIED CORTROPHIN GEL$25,281
- ENVISTA$6,250
- VICTUS$6,250
- TRULIGN TORIC$6,250
- CRYSTALENS$6,250
- STELLARIS$5,000
- NURTEC ODT$449
- ULTOMIRIS$255
- UBRELVY$250
- MIEBO$246
- SOLIRIS$244
- CEQUA$242
- AJOVY$240
- TECFIDERA$233
- QULIPTA$125
- UPLIZNA$125
- XIIDRA$124
- LUMIGAN$112
- COMBIGAN$112
How this compares
$474,677 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 13 | $681,794 |
| Alphagan PBrimonidine Tartrate | 241 | $95,320 |
| RestasisCyclosporine | 77 | $94,608 |
| Nurtec OdtRimegepant Sulfate | 74 | $75,496 |
| XiidraLifitegrast | 33 | $34,848 |
| CequaCyclosporine | 33 | $30,292 |
| LumiganBimatoprost | 56 | $23,073 |
| Restasis MultidoseCyclosporine | 27 | $17,946 |
| QuliptaAtogepant | 15 | $16,885 |
| BotoxOnabotulinumtoxina | 16 | $16,613 |
| Brimonidine Tartrate | 92 | $12,526 |
| Lotemax SmLoteprednol Etabonate | 42 | $10,563 |
| Pyridostigmine Bromide | 88 | $5,701 |
| ErythromycinErythromycin Base | 374 | $3,398 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $3,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $1,538 | $681,79413 claims |
| AbbVieAlphagan P, Restasis, Lumigan, Restasis Multidose, Qulipta | $1,794 | $267,748444 claims |
| PfizerNurtec Odt | $405 | $75,49674 claims |
| Bausch & Lomb Americas Inc.Xiidra | $511 | $34,84833 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $438 | $30,29233 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $6,374 | $10,56342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Sarasota
- Daniel KiernanSarasota$1.7M
- Cathleen McCabeBradenton$2M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.